The use of tocolytic drugs in cases of threatened premature birth after 30 weeks of pregnancy does not improve the baby’s health.
PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d’Oncologia (ICO) and